Canada’s Drug Agency recommends funding lecanemab for early-stage Alzheimer’s disease

Canada’s Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer’s disease if patients meet certain conditions.

Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.

Health Canada approved […] ...